Cover Page

Cite item


Hronic hepatitis B belongs to a category of socially significant diseases due to its wide abundance in the world and high frequency of unfavourable outcomes of this disease. Features of interaction of hepatitis B virus with human immune system, accompanying development of mechanisms of escape from immunological control, is the basis of development of chronic hepatitis B. Molecular-biological features of hepatitis B virus are the basis of the indicated mechanisms, and the content of this review is their examination. Herewith, stages of immunopathogenesis of this disease is the basis of characteristics of interaction of viral proteins with cells of immune system, and isolation of those is accepted in contemporary foreign literature.

About the authors

I. P. Balmasova

Evdokimov Moscow State Medical Stomatological University, Russian University of Peoples’ Friendship

Author for correspondence.
Russian Federation

R. I. Sepiashvili

Evdokimov Moscow State Medical Stomatological University, Russian University of Peoples’ Friendship

Russian Federation

E. S. Malova

Evdokimov Moscow State Medical Stomatological University, Russian University of Peoples’ Friendship

Russian Federation


  1. Сепиашвили Р.И., Балмасова И.П. Кабанова Е.В. и др. Вирус гепатита В: биология, иммунопатогенез, система ЕК/ЕКТ при вирусной персистенции. Журн. микробиол. 2006, 6: 7683.
  2. Cепиашвили РИ.,Балмасова И.П. Иммунные синапсы:от теории к клинической практике. Молекулярная медицина. 2008, 1: 14-22.
  3. Сепиашвили РИ.,Балмасова И.П. Естественные киллеры и биогенные амины: паракринная регуляция в иммунной системе. Росс. физиол. журн. им. И.М.Сеченова. 2005, 8: 927.
  4. Araki K., Miyazaki J., Hino O. et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc. Natl. Acad. Sci. USA. 1989, 86 (1): 207-211.
  5. Balmasova I.P, Yushchuk N.D., Mynbaev O.A. et al. Immunopathogenesis of chronic hepatitis B. World. J. Gastroenterol. 2014, 20 (39): 14156-14171.
  6. Baumert T.F., Thimme R., von Weizsacker F Pathogenesis of hepatitis B virus infection. World. J. Gastroenterol. 2007, 13 (1): 82-90.
  7. Beckebaum S., Cicinnati YR., Zhang X. et al. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology. 2003, 109 (4): 487-495.
  8. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J. Gen. Virol. 2006, 87 (6): 1439-1449.
  9. Biron C.A., Nguyen K.B., Pien G.C. et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Ann. Rev. Immunol. 1999, 17: 189-220.
  10. Block T.M., Guo H., Guo J.T. Molecular virology of hepatitis B virus for clinicians. Clin. Liver. Dis. 2007, 11 (4): 685-706.
  11. Block T.M., Mehta A.S., Blumberg B.S. et al. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity? DNA Cell Biol. 2006, 25 (3): 165-170.
  12. Bonino F., Brunetto M.R.Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J. Hepatol. 2003, 39 (1): 160-163.
  13. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005, 8: 641-654.
  14. Brunetto M.R., Oliveri F., Coco B. et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J. Hepatol. 2002, 36 (2): 263270.
  15. Buchmann P., Dembek C., Kuklick L. et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine. 2013, 31 (3): 1197-1203.
  16. Carson WE., Fehniger T.A., Caligiuri M.A. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur. J. Immunol. 1997, 27 (2): 354-360.
  17. Chang J.J., Lewin S.R. Immunopathogenesis of hepatitis B virus infection. Immunol. Cell. Biol. 2007, 85 (1): 16-23.
  18. Chemin I., Trepo C. Clinical impact of occult HBV infections. J. Clin. Virol. 2005, 34 (1): 15-21.
  19. Chen G.Y, He J.Q., Lv G.C. et al. Involvement of TRAIL up-regulation of CD4+, cD8+ T cells in liver injury in chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2004, 12 (5): 284286.
  20. Chen C.H., Lee C.M., Lu S.N. et al. Clinical significance ofhepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J. Clin. Microbiol. 2005, 43(12): 6000-6006.
  21. Chen M., Sallberg M., Hughes J. et al. Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 2005, 79 (5): 3016-3027.
  22. Das A., Hoare M., Davies N. et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med. 2008, 205 (9): 2111-2124.
  23. Deng L., Tang H. Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. Hepatol. Res. 2011, 41 (11): 1017-1024.
  24. Domingo E., Sheldon J., Perales C. Viral quasispecies evolution. Microbiol. Mol. Biol. Rev. 2012, 76 (2): 159-216.
  25. Dunn C., Brunetto M., Reynolds G. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 2007, 204 (3): 667-680.
  26. Fehr T., Skrastina D., Pumpens P et al. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. USA. 1998, 95 (16): 9477-9481.
  27. Ganem D., Schneider R.J. Hepadnaviridae: The viruses and their replication. In: Knipe D.M. et al. (ed.). Fields Virology, Philadelphia, Lippincott Williams and Wilkins. 2001, p. 2923-2969.
  28. Hui C.K., Lau G.K. Immune system and hepatitis B virus infection. J. Clin. Virol. 2005, 34 (1): 44-48.
  29. Janssen H.L., van Zonneveld M., Schalm S.W Hepatitis B. N. Engl. J. Med. 2004, 350 (26): 27192720.
  30. Kay A., Zoulim F. Hepatitis B virus genetic variability and evolution. Virus. Res. 2007, 127 (2): 164176.
  31. Kimura K., Kakimi K., Wieland S. et al. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J. Immunol. 2002, 169 (9): 5188-5195.
  32. Levrero M., Pollicino T., Petersen J. et al. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 2009, 51 (3): 581-592.
  33. Li L., Liu M., Cheng L.W et al. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand. J. Immunol. 2013, 78 (5): 439446.
  34. Liang T.J. Hepatitis B: the virus and disease. Hepatology. 2009, 49 (5): 13-21.
  35. Liaw YF., Brunetto M.R., Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir. Ther. 2010, 15 (3): 25-33.
  36. Lu YW, Tan T.L., Zhang J. et al. Cellular apoptosis induced by replication of hepatitis B virus: possible link between viral genotype and clinical outcome. Virol. J. 2007, 4: 117.
  37. Malova E.S., Balmasova I.P., Shmeleva E.V et al. Immunologic signs of fibrous changes debut in the liver of patients with chronic hepatitis B. In: Advances in allergy, asthma and immunology: from basic science to clinical management. R.Sepiashvili (ed.). Medimond International Proceedings, 2010.
  38. Mamun A.A., Mahtab M.A., Akbar S.M.F. et al. Impact of viral load on liver damage in Bangladesh. J. Gastroenterol. Hepatol. Res. 2013, 2: 824-826.
  39. Meuleman P, Libbrecht L., Wieland S. et al. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J. Virol. 2006, 80 (6): 2797-2807.
  40. Milich D.R., McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science. 1986, 234 (4782): 1398-1401.
  41. Norder H., Courouce A.M., Magnius L.O. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J. Gen. Virol. 1992, 73 (12): 3141-3145.
  42. Pol S. Natural history of hepatitis B infection. Presse Med. 2006, 35 (2): 308-316.
  43. Ratnam D., Visvanathan K. New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. Hepatol. Int. 2008, 2 (1): 12-18.
  44. Roman S., Panduro A. HBV endemicity in Mexico is associated with HBV genotypes H and G. World J. Gastroenterol. 2013, 19 (33): 5446-5453.
  45. Said Z.N. An overview of occult hepatitis B virus infection. World J. Gastroenterol. 2011, 17 (15): 1927-1938.
  46. Schaefer S. Hepatitis B virus: significance of genotypes. J. Viral. Hepat. 2005, 12 (2): 111-124.
  47. Seeger C., Mason WS. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 2000, 64 (1): 51-68.
  48. Shi Y.H., Shi C.H. Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol. 2009, 15 (25): 3099-3105.
  49. Stoop J.N., van der Molen R.G., Baan C.C. et al. Regulatory T cells to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005, 41 (4): 771-778.
  50. Tamori A., Nishiguchi S., Kubo S. et al. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J. Med. Virol. 2003, 71 (4): 492-498.
  51. Tavis J. The replication strategy of the Hepadanaviruses. Viral Hepatitis Rev. 1996, 2: 205-218.
  52. van der Molen R.G., Sprengers D., Binda R.S. et al. Functional impairment of myeloid and plas-macytoid dendritic cells of patients with chronic hepatitis B. Hepatology. 2004, 40 (3): 738-746.
  53. Vanlandschoot P., Cao T., Leroux-Roels G. The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure. Antiviral. Res. 2003, 60 (2): 67-74.
  54. Wiegand J., Hasenclever D., Tillmann H.L. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir. Ther. 2008, 13 (2): 211-220.
  55. Wieland S., Thimme R., Purcell R.H. et al. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. USA. 2004, 101 (17): 6669-6674.
  56. Wong D.K., Huang F.Y., Lai C.L. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011, 54 (3): 829-836.
  57. You J., Sriplung H., Geater A. et al. Effect of viral loa d on T-lymphocyte failure in patients with chronic hepatitis B. World J. Gastroenterol. 2008, 14 (7): 1112-1119.
  58. Zhang H.H., Mei M.H., Fei R. et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J. Viral. Hepat. 2010, 17 (1): 34-43.

Copyright (c) 2016 Balmasova I.P., Sepiashvili R.I., Malova E.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies